Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADX-MAPT is an investigational small interfering RNA (siRNA) therapeutic targeting the microtubule-associated protein tau (MAPT), also known as TAU. It is designed to inhibit the expression of tau protein, which plays a key role in neurodegenerative diseases such as Alzheimer's disease. By inhibiting tau, ADX-MAPT aims to reduce pathological tau accumulation and its associated neurotoxicity. The drug is being developed by ADARx Pharmaceuticals and is currently at the discovery stage for the treatment of Alzheimer's disease[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADX-MAPT.